Cargando…

Systematic review of studies comparing infliximab and adalimumab in autoimmune uveitis

OBJECTIVE: This study aimed to review effectiveness studies comparing two biological anti-tumour necrosis factor agents, adalimumab (ADA) and infliximab (IFX), in the management of autoimmune uveitis. METHODS: A systematic search was conducted across PubMed, Scopus, Web of Science and Google Scholar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mase, Oliver, Qasem, Mustafa, Beare, Nicholas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Uveitis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277136/ https://www.ncbi.nlm.nih.gov/pubmed/37493653 http://dx.doi.org/10.1136/bmjophth-2023-001303

Ejemplares similares

Adalimumab in patients with vision-threatening uveitis: real-world clinical experience
por: Tang Lee Say, Timothy Lee, et al.
Publicado: (2021)

Systemic Administration of Acazicolcept, a Dual CD28 and Inducible T cell Costimulator Inhibitor, Ameliorates Experimental Autoimmune Uveitis
por: Wilson, Leslie, et al.
Publicado: (2023)

Comprehensive LncRNA and Potential Molecular Mechanism Analysis in Noninfectious Uveitis
por: Lu, Shiheng, et al.
Publicado: (2023)

Risk factors for ocular toxoplasmosis among uveitis patients in Kinshasa, DR Congo
por: Nsiangani Lusambo, Nadine, et al.
Publicado: (2023)

Bibliometric analysis of the uveitis literature and research trends over the past two decades
por: Gao, Tingxiao, et al.
Publicado: (2023)

Occurrence of uveitis in a population-based cohort of inflammatory bowel diseases followed for 10 years: an observational study
por: Granstam, Elisabet, et al.
Publicado: (2023)

Healthcare costs among patients with macular oedema associated with non-infectious uveitis: a US commercial payer’s perspective
por: Hariprasad, Seenu M, et al.
Publicado: (2021)

Managing cataract surgery in patients with uveitis
por: Harapriya, Aravind, et al.
Publicado: (2019)

Colombian ocular inflammatory diseases epidemiology study (COIDES): prevalence, incidence and sociodemographic characterisation of Scleritis in Colombia, 2015–2020
por: Cifuentes-González, Carlos, et al.
Publicado: (2022)

Evaluation of the Dose-Dependent Inflammatory Response and No-Observable Adverse Effect Level of Intravitreal Endotoxin in the African Green Monkey
por: Corey, Tatiana M., et al.
Publicado: (2022)

Tuberculous Uveitis
por: Abu El-Asrar, Ahmed M., et al.
Publicado: (2009)

Behçet's Uveitis
por: Tugal-Tutkun, Ilknur
Publicado: (2009)

Emergent Infectious Uveitis
por: Khairallah, Moncef, et al.
Publicado: (2009)

Viral anterior uveitis
por: Gozzi, Fabrizio, et al.
Publicado: (2022)

Laser flare photometry in uveitis
por: Kesim, Cem, et al.
Publicado: (2022)

Fluorescein and Indocyanine Green Angiography for Uveitis
por: Herbort, Carl P
Publicado: (2009)

Rickettsial disease: An underestimated cause of posterior uveitis
por: Abroug, Nesrine, et al.
Publicado: (2022)

Appraisal, Work-Up and Diagnosis of Anterior Uveitis: A Practical Approach
por: Herbort, Carl P.
Publicado: (2009)

Interpreting posterior uveitis by integrating indocyanine green angiography, optical coherence tomography, and optical coherence tomography angiography data: A narrative review
por: Chandrasekaran, Priya R., et al.
Publicado: (2022)

Fuchs' Uveitis: Failure to Associate Vitritis and Disc Hyperfluorescence with the Disease is the Major Factor for Misdiagnosis and Diagnostic Delay
por: Bouchenaki, Nadia, et al.
Publicado: (2009)

Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis
por: Liu, Weishai, et al.
Publicado: (2023)

Use of Adalimumab in young patients with chronic uveitis in whom infliximab loses its efficacy
por: Giani, TG, et al.
Publicado: (2008)

Inflammatory Choroidal Neovascularization
por: Neri, Piergiorgi, et al.
Publicado: (2009)

Differential Diagnosis of Retinal Vasculitis
por: Abu El-Asrar, Ahmed M., et al.
Publicado: (2009)

An excursion into ocular tuberculosis
por: Yen, Dayna J.S., et al.
Publicado: (2022)

Adalimumab Induced or Provoked MS in Patient with Autoimmune Uveitis: A Case Report and Review of the Literature
por: Alnasser Alsukhni, Rana, et al.
Publicado: (2016)

Comparing adalimumab and infliximab in the prevention of postoperative recurrence of Crohn’s disease: a systematic review and meta-analysis
por: Gangwani, Manesh Kumar, et al.
Publicado: (2023)

Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis
por: Wang, Han, et al.
Publicado: (2022)

Profile of adalimumab and its potential in the treatment of uveitis
por: Balevic, Stephen J, et al.
Publicado: (2016)

Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis
por: Yang, Hua-Hua, et al.
Publicado: (2022)

Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab
por: Rissel, Florian, et al.
Publicado: (2023)

Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis
por: Pan, Ran, et al.
Publicado: (2022)

Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review
por: Ming, Shuai, et al.
Publicado: (2018)

Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis
por: Savelkoul, Edo H J, et al.
Publicado: (2022)

Outcome of adalimumab monotherapy in paediatric non-infectious uveitis
por: Al-Julandani, DA, et al.
Publicado: (2023)

The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis
por: Park, Sung Eun, et al.
Publicado: (2021)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
por: Kim, Eun Soo
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5hj73q5ggffiq1l7qk485bogvs